Gilead Sciences to Acquire Tubulis to Advance Targeted Cancer Therapies - The Healthcare Technology Report.
HealthcareMerger
Gilead Sciences→Tubulis
May 4, 2026
Gilead Sciences — Acquisitions & M&A Deals
7 dealsTracking 7 M&A deals by Gilead Sciences.
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel - citybiz
HealthcareMerger
Gilead Sciences→Arcellx
Apr 28, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
HealthcarePlatform
Gilead Sciences→Arcellx
Apr 28, 2026
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis
HealthcareBolt-on
Gilead Sciences→Tubulis
Apr 7, 2026
T/A - GILEAD SCIENCES, INC. (0000882095) (Filed by) — SEC SC TO Filing
HealthcareCaliforniaMerger
Gilead Sciences→Arcellx
Apr 1, 2026
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio - Proactive financial news
HealthcareOther
Gilead Sciences→Ouro Medicines
Mar 24, 2026
Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx - Pharmaceutical Executive
HealthcareMerger
Gilead Sciences→Arcellx
Feb 23, 2026